Full Text Journal Articles in
Journal Urol Oncol

Advertisement

Find full text journal articles






Penile-sparing surgery for patients with superficial or initially invasive squamous cell carcinoma of the penis: long-term oncological outcomes.

Stefano Luzzago, Alessandro Serino, Gaetano Aurilio, Francesco A Mistretta, Mattia Luca Piccinelli, Vito Lorusso, Michele Morelli, Roberto Bianchi, Michele Catellani, Gabriele Cozzi, Ettore Di Trapani, Antonio Cioffi, Elena Verri, Matteo Ferro, Maria Cossu Rocca, Deliu-Victor Matei, Franco Nolè, Ottavio de Cobelli, Gennaro Musi,

<h4>Purpose</h4>To report long-term oncological outcomes after penile-sparing surgery (PSS) for superficial (Ta-Tis) or initially invasive (T1) penile cancer patients.<h4>Methods</h4>We retrospectively analysed 85 patients with Ta/Tis/T1cN0cM0 penile cancer (1996-2018). All patients underwent PSS: circumcision, excision or laser ablation. First, Kaplan-Meier plots and multivariable Cox regression models tested tumor recurrence rates (any ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma.

Alberto C Pieretti, Mary E Westerman, Alexandria Childs, Niki Millward, Daniel D Shapiro, Kanishka Sircar, Priya Rao, Eric Jonasch, Matthew T Campbell, Nizar M Tannir, Surena F Matin, Christopher G Wood, Jose A Karam,

<h4>Purpose</h4>The presence of sarcomatoid features and/or lymph node-positive disease may be associated with a worse prognosis in chromophobe renal cell carcinoma (ChRCC). We sought to better characterize patients' long-term outcomes with these features compared with those without these features.<h4>Materials and methods</h4>We identified 300 patients treated for sporadic, unilateral, nonmetastatic ChRCC ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Renal mass biopsy: A strategy to reduce associated costs and morbidity when managing localized renal masses.

Abhishek Srivastava, Robert N Uzzo, Jennifer Lee, Eric Cho, Alex Grieco, Selma Masic, Elizabeth Handorf, David Y T Chen, Rosalia Viterbo, Richard E Greenberg, Marc C Smaldone, Alexander Kutikov, Robert G Uzzo,

<h4>Introduction and objectives</h4>Renal mass biopsy (RMB) has not been widely adopted in evaluating small renal mass due to concerns for safety, efficacy, and its perceived lack of consequence on management decisions. We assess the potential cost savings and morbidity avoidance of routine RMB on cT1 renal masses undergoing robotic-assisted partial ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Identification of oncological characteristics associated with improved overall survival in patients with adrenocortical carcinoma treated with adjuvant radiation therapy: Insights from the National Cancer Database.

Kevin B Ginsburg, Akhil A Chandra, Jared P Schober, Elizabeth A Handorf, Robert G Uzzo, Richard E Greenberg, David Yt Chen, Rosalia Viterbo, Marc C Smaldone, Alexander Kutikov, Mark A Hallman, Andres F Correa,

<h4>Objectives</h4>To test for an association between oncological risk factors and overall survival in patients with non-metastatic adrenocortical carcinoma treated with adjuvant radiation therapy at high-risk for recurrence per NCCN guidelines.<h4>Materials and methods</h4>We analyzed data from patients undergoing surgical resection with or without aRT in the NCDB from 2004 to 2017. ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



The association of phosphodiesterase-5 inhibitors with the biochemical recurrence-free and overall survival of patients with prostate cancer following radical prostatectomy.

Kelsey T Danley, Alan Tan, William J Catalona, Robin Leikin, Irene Helenowski, Borko Jovanovic, Michael Gurley, Timothy M Kuzel,

<h4>Purpose</h4>To determine whether phosphodiesterase-5 inhibitor documentation is associated with biochemical relapse-free and overall survival of patients with prostate cancer treated with radical prostatectomy.<h4>Materials and methods</h4>We undertook a retrospective cohort analysis of 3,100 patients with prostate cancer treated with radical prostatectomy between 2003 and 2015. The patients were categorized as a ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition.

Andrea Necchi, Daniele Raggi, Andrea Gallina, Marco Bandini, Joep J de Jong, Laura Marandino, Alberto Briganti, Francesco Montorsi, Elai Davicioni, Yair Lotan, Ewan A Gibb,

<h4>Purpose</h4>Clinical high-grade (HG) T1 non-muscle invasive bladder cancer (NMIBC) represents a significant risk to patients, but these patients are not typically offered neoadjuvant therapies, including immune therapy. In this study, we determine whether patients with HG clinical T1 or T2 bladder urothelial carcinoma (UC) have profiles that predict the potential ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma.

Yudai Ishiyama, Tsunenori Kondo, Yuki Nemoto, Yuki Kobari, Hiroki Ishihara, Hidekazu Tachibana, Kazuhiko Yoshida, Yasunobu Hashimoto, Toshio Takagi, Junpei Iizuka, Kazunari Tanabe,

<h4>Objectives</h4>The use of antibiotics alters gut microbiota and has been reported to impact outcomes in immune checkpoint inhibitor (ICI) treatment in various types of cancer. We investigated the impact of antibiotics on patients with metastatic urothelial carcinoma (mUC) treated with pembrolizumab.<h4>Materials and methods</h4>The data of 67 patients with chemotherapy-resistant mUC ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology.

Tanya B Dorff, Brock O'Neil, Karen E Hoffman, Daniel W Lin, Kevin R Loughlin, Marc Dall'Era,

Major changes in the field of prostate cancer over the last 25 years include the implementation of prostate specific antigen screening and the recognition that BRCA confers hereditary risk of prostate cancer. Quality of life and survivorship have driven risk stratification for localized prostate cancer, facilitated by molecular signatures and ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Letter to the Editor, Re: Reitblat et al. 2021.

Casey W Williamson, Loren K Mell,

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?

Gerald Bastian Schulz, Rumyana Todorova, Till Braunschweig, Severin Rodler, Yannic Volz, Lennert Eismann, Paulo Pfitzinger, Friedrich Jokisch, Alexander Buchner, Christian Stief, Doris Mayr, Jozefina Casuscelli,

<h4>Introduction</h4>For cisplatin-ineligible patients, approval of first-line immune-checkpoint inhibitor therapy relies on the programmed death ligand 1 (PD-L1) expression assay employed, namely, the combined positive score (CPS) or immune cell (IC) score. This study compares PD-L1 diagnostic scores and positivity in primary and matched metastatic bladder cancer tissue.<h4>Methods</h4>A total of 108 ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Local anesthesia for percutaneous US/CT-guided bipolar radiofrequency ablation of small renal masses: A safe and feasible alternative.

Yifan Sun, Wei Wang, Qing Zhang, Xiaozhi Zhao, Guanchen Zhu, Jiange Hao, Yansheng Kan, Hongqian Guo,

<h4>Purpose</h4>This study is to evaluate the safety and feasibility of local anesthesia (LA) for percutaneous ultrasound/computed tomography (US/CT)-guided bipolar radiofrequency ablation (RFA) for small renal masses (SRMs) by comparing the LA with general anesthesia.<h4>Materials and methods</h4>A retrospective review was carried out between January 2018 to June 2020, 102 patients with ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Definitive surgical therapy for refractory radiation cystitis: Evaluating effectiveness, tolerability, and extent of surgical approach.

Isamu Tachibana, Adam C Calaway, Zain Abedali, Konrad M Szymanski, Matthew J Mellon, Timothy A Masterson, Clint Cary, Hristos Z Kaimakliotis, Ronald S Boris,

<h4>Introduction and objective</h4>The management of severe symptoms secondary to radiation changes to the bladder can be difficult. Many patients often endure costly procedures, hospitalizations, transfusions, and physician visits for intractable symptoms. Our aim was to evaluate the short-term efficacy and feasibility of urinary diversion in patients with severe, debilitating symptoms ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis.

Ekaterina Laukhtina, Keiichiro Mori, David D Andrea, Marco Moschini, Mohammad Abufaraj, Francesco Soria, Andrea Mari, Wojciech Krajewski, Simone Albisinni, Jeremy Yuen-Chun Teoh, Fahad Quhal, Reza Sari Motlagh, Hadi Mostafaei, Satoshi Katayama, Nico С Grossmann, Pawel Rajwa, Dmitry Enikeev, Kristin Zimmermann, Harun Fajkovic, Petr Glybochko, Shahrokh F Shariat, Benjamin Pradere, ,

We aimed to conduct a systematic review and meta-analysis assessing the incidence and risk factors of urethral recurrence (UR) as well as summarizing data on survival outcomes in patients with UR after radical cystectomy (RC) for bladder cancer. The MEDLINE and EMBASE databases were searched in February 2021 for studies ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Prognostic nutritional index and prognosis in renal cell carcinoma: A systematic review and meta-analysis.

Sun Il Kim, Se Joong Kim, Seong Jang Kim, Dae Sung Cho,

<h4>Purpose</h4>To perform a systematic review and meta-analysis of the Prognostic Nutritional Index (PNI) as a prognostic factor for renal cell carcinoma (RCC).<h4>Materials and methods</h4>Eligible studies that evaluated the prognostic impact of pretreatment PNI in RCC patients were identified by comprehensive searching the electronic databases PubMed, Cochrane Central Search library, and ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



The stanford prostate cancer calculator: Development and external validation of online nomograms incorporating PIRADS scores to predict clinically significant prostate cancer.

Nancy N Wang, Steve R Zhou, Leo Chen, Robert Tibshirani, Richard E Fan, Pejman Ghanouni, Alan E Thong, Katherine J To'o, Kamyar Amirkhiz, Jeffrey W Nix, Jennifer B Gordetsky, Preston Sprenkle, Soroush Rais-Bahrami, Geoffrey A Sonn,

<h4>Background</h4>While multiparametric MRI (mpMRI) has high sensitivity for detection of clinically significant prostate cancer (CSC), false positives and negatives remain common. Calculators that combine mpMRI with clinical variables can improve cancer risk assessment, while providing more accurate predictions for individual patients. We sought to create and externally validate nomograms incorporating ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Prognostic relevance of ABO blood group system in non-metastatic renal cell carcinoma: An analysis of two independent European cohorts with long-term follow-up.

Dominik A Barth, Nazanin Sareban, Andrea K Lindner, Louisa A J Daller, Eva Maria Matzhold, Georg Hutterer, Maria Smolle, Johannes Mischinger, Jakob M Riedl, Maximilian Seles, Sebastian Mannweiler, Thomas Bauernhofer, Karl Pummer, Renate Pichler, Richard Zigeuner, Peter Schlenke, Martin Pichler,

<h4>Background</h4>The ABO blood group system has been previously discussed as a risk factor to develop, as well as a prognostic factor in non-metastatic renal cell carcinoma (RCC). Controversial findings have been reported in different populations of RCC patients with rather short follow-up periods. In this study, we aimed to clarify ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Applicant perceptions of virtual interviews for society of urologic oncology fellowships during the COVID-19 pandemic.

John L Gore, Sima P Porten, Jeffrey S Montgomery, Robert J Hamilton, Maxwell V Meng, Wade J Sexton, Sarah P Psutka,

The COVID-19 public health emergency forced the conversion of in-person SUO fellowship interviews into virtual interviews. We sought to understand applicant perspectives and preferences related to virtual interviews and whether programs should consider virtual interviews in the future. We distributed a survey to 2020 SUO Fellowship interview participants at 4 ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Real-world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1/L1 inhibitor therapy: A Medicare claims database analysis.

Alicia K Morgans, Zsolt Hepp, Sonali N Shah, Anne Shah, Allison Petrilla, Mary Small, Guru Sonpavde,

<h4>Background</h4>Several programmed death-1 or death-ligand 1 (PD-1/L1) inhibitors are approved first- or second-line therapies for locally advanced or metastatic urothelial carcinoma (la/mUC); however, clinical trials show that only ∼20% of patients respond and all ultimately progress. This study elucidated real-world treatment patterns, healthcare resource utilization (HRU), and economic burden among ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Managing female sexual dysfunction.

Sarah S Arthur, Caroline S Dorfman, Lisa A Massa, Rebecca A Shelby,

<h4>Objective</h4>Provide an overview of sexual dysfunction in female urologic cancer patients, approaches for assessing sexual problems, and interventions to treat sexual dysfunction in this patient population.<h4>Methods</h4>A review of the literature in urologic oncology was conducted. Research on other female pelvic cancers with similar treatments was also reviewed.<h4>Results</h4>Sexual health is an ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of penile cancer.

Timothy A Masterson, Scott T Tagawa,

Squamous cell carcinoma of the penis (SCCP) is uncommon in some countries (including the U.S.), but is an important malignancy elsewhere. As a rare disease, progress has been slow compared to more common tumor types discussed in this anniversary issue and most often limited to single-center or retrospective datasets.  In ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Comprehensive genomic profiling of histologic subtypes of urethral carcinomas.

Joseph Jacob, Andrea Necchi, Petros Grivas, Michael Hughes, Thomas Sanford, Mehdi Mollapour, Oleg Shapiro, Ahmad Talal, Ethan Sokol, Jo-Anne Vergilio, Jonathan Killian, Douglas Lin, Erik Williams, Julie Tse, Shakti Ramkissoon, Eric Severson, Amanda Hemmerich, Naomi Ferguson, Clair Edgerly, Daniel Duncan, Richard Huang, Jon Chung, Russell Madison, Brian Alexander, Jeffrey Venstrom, Prasanth Reddy, Kimberly McGregor, Julia Elvin, Alexa Schrock, Natalie Danziger, Dean Pavlick, Jeffrey Ross, Gennady Bratslavsky,

<h4>Background</h4>Carcinoma of the urethra (UrthCa) is an uncommon Genitourinary (GU) malignancy that can progress to advanced metastatic disease.<h4>Methods</h4>One hundred twenty-seven metastatic UrthCa underwent hybrid capture-based comprehensive genomic profiling to evaluate all classes of genomic alterations (GA). Tumor mutational burden was determined on up to 1.1 Mbp of sequenced DNA, and ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



The impact of single-nucleotide polymorphisms on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer in a genome-wide association study.

Shohei Nagakawa, Masaki Shiota, Naohiro Fujimoto, Yoshiaki Yamamoto, Leandro Blas, Shigehiro Tsukahara, Takashi Matsumoto, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Takeshi Uchiumi, Hideyasu Matsuyama, Masatoshi Eto,

<h4>Objective</h4>Bacillus Calmette-Guérin (BCG) instillation therapy is widely used to reduce intravesical recurrence in non-muscle invasive bladder cancer (NMIBC). In this study, we aimed to reveal the genetic variations associated with intravesical recurrence after BCG therapy for NMIBC in a genome-wide association study (GWAS).<h4>Materials and methods</h4>This study included Japanese patients with ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



A 25 year perspective on advances in the pathologic assessment and diagnosis of urologic cancers.

Donna E Hansel,

Over the past 25 years, diagnostic categories in genitourinary pathology have changed dramatically. Prostate cancer reporting incorporated numerous new variant categories, recognized the importance of intraductal carcinoma, and introduced the concept of Grade Groups. Pathologic diagnosis of bladder cancer not only added new variant categories, but also modified the grading ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Metastasis-directed radiation therapy after radical cystectomy for bladder cancer.

Andre F Miranda, Jeffrey M Howard, Mark McLaughlin, Xiaosong Meng, Timothy Clinton, Öner Şanli, Aurelie Garant, Aditya Bagrodia, Vitaly Margulis, Yair Lotan, Raquibul Hannan, Neil Desai, Solomon L Woldu,

<h4>Purpose</h4>Metastasis-directed radiation therapy (MDRT) may improve oncologic and quality of life outcomes in patients with metastatic cancer, but data on its use in metastatic bladder cancer is severely limited. We sought to review our institutional experience with MDRT in patients with metastatic bladder cancer following radical cystectomy.<h4>Materials and methods</h4>We reviewed ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Serum uric acid variability increases the risk of postoperative chronic kidney disease in patients with renal cell carcinoma after radical nephrectomy.

Xin Li, Zhen Li, Xiaojing Wu, Muyin Zhang, Lili Xu, Xu Hao, Hao Li, Panpan Qiao, Weiming Wang,

<h4>Objective</h4>Serum uric acid (SUA) level is associated with the progression of chronic kidney disease (CKD). However, little is known about the predictive value of SUA variability for postoperative CKD in patients with renal cell carcinoma after radical nephrectomy. We aimed to investigate the association of SUA variability with postoperative CKD ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
0.9226 s